| Document Date: 2012-06-28 04:30:05
Open Document File Size: 377,08 KBShare Result on Facebook
Company Gilead Sciences / Medical Affairs Gilead Sciences Inc. / / Country United States / / Event FDA Phase / Product Release / / Facility Pipeline Single Agents Fixed-Dose Combinations Single-Tablet Regimens Current Medications Viread / Pipeline Elvitegravir Cobicistat / / IndustryTerm HIV Treatment / technology transfer / manufacturing process / / MedicalCondition HIV / HIV/AIDS / liver disease / / Organization Federal Trade Commission / World Health Organization / / Person Gregg Alton / / Position Executive Vice President / / Product Emtriva / HIV Products / Viread / Atripla / Truvada / Access Program / Emtriva® Emtricitabine / /
SocialTag |
GS[removed]A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ADEFOVIR DIPIVOXIL WHEN GIVEN IN COMBINATION WITH HAART FOR THE TREATMENT OF HIV-INFECTED PATIENTS WHO HAVE FAILED THEIR FIRST HAART REGIMEN